|
Oplopanax horridus |
Oplopanax horridus |
| O-68: DEVIL’S CLUB, AN UNEXPLORED NORTH AMERICAN BOTANICAL, FOR CANCER CHEMOPREVENTION: A PHYTOCHEMICAL AND PHARMACOLOGICAL INVESTIGATION Chong-Zhi Wang, Anna Fishbein, Guang-Jian Du,, Lian-Wen Qi, Sangeeta R. Mehendale, Shao-Ping Li, and Chun-Su Yuan. Devil’s club, or Oplopanax horridus (OPH), widely distributed in the west of North America, belongs to the genus Oplopanax, which consists of three species (O. elatus, O. japonicus and O. horridus). Although many studies on the other two species were carried out, phytochemical and pharmacological investigations on OPH were limited, especially its anticancer related studies. After comparing differences of HPLC fingerprint and antiproliferative potential among different plant parts of OPH, the root bark was selected to perform further phytochemical isolation to prepare active anticancer fractionations and compounds. A hydrophobic fraction showed the most potent antiproliferative effects on human HCT-116 and SW-480 colorectal cancer cells. Subsequent isolation of the hydrophobic fraction gave a series of polyynes, in which two novel compounds, Oplopantriol A and Oplopantriol B (see figure below), were obtained. Pharmacological studies showed that two polyynes, including a novel compound (Oplopantriol A), possessed strong cancer cell inhibitor. 2010 The IC50 of these two polyynes were observed at 1-5 μM on the colorectal cancer cells. Treatment with active fraction and compounds noticeably induced apoptosis, and distinctly induced the G2/M phase arrest of the cell cycle in a time- and concentration-dependent manner. These results suggested that active OPH fraction and selected polyynes had potential antiproliferative activities on human colorectal cancer cells. The observed anticancer effects could be related to induction of apoptosis and regulation of cell cycle transition. Joint Annual Meeting of the American Society of Pharmacognosy & the Phytochemical Society of North America Natural Solutions to 21st Century Problems – from Discovery to Commercialization. Abstract. | |
